Micafungine Accord

Micafungin, the active ingredient in Micafungine Accord, is an echinocandin presented as an intravenous formulation for hospital use. It treats serious fungal infections such as invasive candidiasis, Candida esophagitis, peritonitis and bloodstream infections in immunocompromised patients. It is effective against most Candida species, including those resistant to azole therapy.

GNH USA supplies Micafungine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality‑assured products and reliable logistics across global markets.

Micafungin is used to treat invasive fungal infections caused by Candida species.

- Invasive candidiasis: eradicates bloodstream and deep‑tissue Candida infections. - Candida esophagitis: resolves esophageal lesions and associated symptoms. - Candida peritonitis: clears intra‑abdominal Candida infection. - Candida bloodstream infections: eliminates fungemia and prevents dissemination.

Micafungin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fever: transient temperature rise during or after infusion. - Nausea: mild to moderate upset stomach. - Headache: occasional mild headache. - Infusion‑related reactions: flushing, chills, or rigors during administration. - Elevated liver enzymes: transient increase in ALT/AST. - Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects: - Hepatic failure: severe liver dysfunction requiring monitoring. - Severe allergic reactions: anaphylaxis with respiratory distress or shock. - Acute renal impairment: sudden rise in serum creatinine. - Severe hypotension: marked drop in blood pressure during infusion. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: serious skin blistering. - Cardiovascular events: arrhythmias or myocardial infarction.

When using Micafungin, clinicians should observe specific safety measures to minimize risks.

- Renal function: monitor serum creatinine and urine output. - Hepatic function: assess liver enzymes before and during therapy. - Concomitant antifungals: avoid overlapping use with other echinocandins. - Pregnancy and lactation: prescribe only if potential benefit outweighs risk. - Drug interactions: review patient’s medication list for CYP inducers or anticoagulants. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce micafungin exposure. - Co‑administration with other echinocandins: increased risk of toxicity. - High‑dose azoles (e.g., voriconazole): potential additive hepatotoxicity.

Moderate Interactions (Monitor Closely): - Azole antifungals (fluconazole, itraconazole): may increase liver enzyme levels. - Immunosuppressants (cyclosporine, tacrolimus): monitor blood concentrations. - Anticoagulants (warfarin): watch for altered INR values.